NRx Pharmaceuticals, Inc.
Every calculator, already run for NRXP
Open the full toolkit →You have the numbers on NRXP. Get the argument.
A written report on which of these readings actually decide the outcome for NRx Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering NRXPAnalyst Price Target Disagreement for NRx Pharmaceuticals, Inc.
Wall Street's bull case implies +1376% from the current price; the bear case implies +201%. A 1175% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NRXP
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides p…
NRXP — frequently asked
Is NRXP a buy right now?
Wall Street's consensus rating on NRx Pharmaceuticals, Inc. is Strong Buy across 4 analysts, with a mean price target of $38.25 (+1052% vs. the current $3.32). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is NRXP's next earnings date?
NRx Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 12, 2026. A full NRXP research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for NRx Pharmaceuticals, Inc.?
Analysts covering NRx Pharmaceuticals, Inc. (NRXP) range from a bear-case target of $10.00 to a bull-case high of $49.00, with a mean consensus target of $38.25 across 4 analysts. The spread of $39.00 (1175% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare NRx Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For NRx Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NRXP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on NRx Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.